Gradient Bioconvergence (CEO Nam In-bong), a subsidiary of Gradient, announced on the 10th that it will participate in the European Society for Medical Oncology (ESMO 2025), which will be held in Berlin, Germany from October 17th to 21st (local time). This will be the second consecutive year of participation, following last year.
Gradient Bioconvergence will operate its own booth during the conference and introduce its core technologies, including ▲patient-derived organoid (PDO) banking ▲human induced pluripotent stem cell (hiPSC)-based brain organoid model ▲AI-based target discovery platform, and seek business collaboration opportunities with global pharmaceutical and bio companies.
The company's PDO banking library, comprising approximately 1,000 types, is built with clinical and genomic data (NGS), enabling it to be utilized for evaluating the efficacy of new drug candidates and discovering new targets. In particular, a model co-cultivating hiPSC-derived microglia with brain organoids can recapitulate neuroinflammatory responses, and is being applied to research on degenerative brain diseases such as Alzheimer's and Parkinson's.
Additionally, Gradient Bioconvergence is introducing a target discovery platform that combines PDO-based big data with its proprietary AI algorithm. This platform utilizes step-by-step statistical filtering and genomic analysis to identify cancer-related targets previously inaccessible. These candidate targets are validated using the CRISPR system, increasing the potential for new drug development.
The company is conducting joint research with a global pharmaceutical company based on the new kinase target 'GBC-11004' discovered through this platform.
CEO Nam In-bong said, “We are focusing on increasing the predictability and efficiency of new drug development by combining patient-derived organoid technology with AI-based analysis systems,” and added, “Through this participation in ESMO, we plan to share our research results internationally and continue discussions to expand partnerships.”
- See more related articles
You must be logged in to post a comment.